Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition

Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition

Show other versions (1)

Mass photometry data and analysis code presented in the pablication "Oligomerisation-driven avidity controls SARS-CoV-2 cellular binding and inhibition"

Bibliographic Details
Main Author:	Asor, R
Other Authors:	Kukura, P
Format:	Dataset
Language:	English
Published:	University of Oxford 2024

Similar Items

Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition
by: Asor, R, et al.
Published: (2024)

Cooperativity and induced oligomerization control the interaction of SARS-CoV-2 with its cellular receptor and patient-derived antibodies
by: Asor, R, et al.
Published: (2024)

Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination
by: Laura Garcia, et al.
Published: (2022-07-01)

Blood collection tube and anticoagulant influence on SARS-CoV-2 antibody and avidity levels
by: Nicholas C. Castro, et al.
Published: (2024-07-01)

Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection
by: Alexandra Tauzin, et al.
Published: (2022-03-01)

Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection
by: Jonathon M. Monroe, et al.
Published: (2022-11-01)

Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV‑2 Spike by Single Particle Mass Analyses
by: Victor Yin, et al.
Published: (2021-11-01)

Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity
by: Etsuhisa Takahashi, et al.
Published: (2023-07-01)

Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients
by: Stavroula Labropoulou, et al.
Published: (2022-04-01)

Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients
by: Andrew D. Moura, et al.
Published: (2021-09-01)

Drug-induced phospholipidosis is not correlated with the inhibition of SARS-CoV-2 - inhibition of SARS-CoV-2 is cell line-specific
by: Viktoria Diesendorf, et al.
Published: (2023-08-01)

Oligomerization-dependent beta-structure formation in SARS-CoV-2 envelope protein
by: Surya, Wahyu, et al.
Published: (2023)

Orchestrating Binding Interactions and the Emergence of Avidity Driven Therapeutics
by: Eden Kapcan, et al.
Published: (2023-03-01)

LRRC15 inhibits SARS-CoV-2 cellular entry in trans.
by: Jaewon Song, et al.
Published: (2022-10-01)

SARS-CoV-2 cellular tropism
by: Valeria Cagno
Published: (2020-05-01)

Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination
by: Francesca Dapporto, et al.
Published: (2022-01-01)

Production and characterisation of a SARS-CoV-2 S-protein RBD homodimer with increased avidity for specific antibodies
by: A. A. Derkaev, et al.
Published: (2023-04-01)

Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera
by: Myriam Belén González Viacava, et al.
Published: (2022-01-01)

Transient oligomerization of the SARS-CoV N protein--implication for virus ribonucleoprotein packaging.
by: Chung-ke Chang, et al.
Published: (2013-01-01)

Polyunsaturated ω-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry
by: Anna Goc, et al.
Published: (2021-03-01)

The natural tannins oligomeric proanthocyanidins and punicalagin are potent inhibitors of infection by SARS-CoV-2
by: Hsiao-Fan Chen, et al.
Published: (2023-08-01)

Inhibition of SARS-CoV-2 infection in cellular systems using engineered trimeric receptor-binding domain of spike protein
by: Angela Rose Liu, et al.
Published: (2023-03-01)

Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2
by: Ting Zhang, et al.
Published: (2023-01-01)

Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection
by: Victor Manuylov, et al.
Published: (2022-03-01)

Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
by: Wenjuan Du, et al.
Published: (2023-02-01)

Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor
by: Jinsung Yang, et al.
Published: (2020-09-01)

Does SARS-CoV-2 bind to human ACE2 stronger than SARS-CoV?
by: Nguyen, HL, et al.
Published: (2020)

Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization
by: Shilei Ding, et al.
Published: (2020-10-01)

Glucocorticoids Bind to SARS-CoV-2 S1 at Multiple Sites Causing Cooperative Inhibition of SARS-CoV-2 S1 Interaction With ACE2
by: Hassan Sarker, et al.
Published: (2022-06-01)

High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: potential relevance for protective humoral immunity
by: Georg Bauer
Published: (2022-03-01)

Structural Dissection of Viral Spike-Protein Binding of SARS-CoV-2 and SARS-CoV-1 to the Human Angiotensin-Converting Enzyme 2 (ACE2) as Cellular Receptor
by: Deborah Giordano, et al.
Published: (2021-08-01)

Membrane cholesterol regulates the oligomerization and fusogenicity of SARS-CoV fusion peptide: implications in viral entry
by: Meher, Geetanjali, et al.
Published: (2023)

Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2
by: Raquel Arroyo, et al.
Published: (2021-07-01)

The complex proteolipidic behavior of the SARS-CoV-2 envelope protein channel: weak selectivity and heterogeneous oligomerization
by: Surya, Wahyu, et al.
Published: (2023)

Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity
by: Jianbo Dong, et al.
Published: (2020-01-01)

Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
by: Romain Rouet, et al.
Published: (2021-01-01)

Synthetic carbohydrate-binding agents neutralize SARS-CoV-2 by inhibiting binding of the spike protein to ACE2
by: Oscar Francesconi, et al.
Published: (2022-05-01)

From Free Binding Energy Calculations of SARS-CoV-2—Receptor Interactions to Cellular Immune Responses
by: Michael O. Glocker, et al.
Published: (2022-02-01)

Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2
by: Yixin Xie, et al.
Published: (2020-12-01)

Analysis and Identification of Bioactive Compounds of Cannabinoids in Silico for Inhibition of SARS-CoV-2 and SARS-CoV
by: Chenxiao Chen, et al.
Published: (2022-11-01)